Clinical Trial Update: An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of Nasacort AQ in children aged 2-5 years with perennial allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis Perennial

Drugs mentioned

• Nasacort AQ (triamcinolone acetonide)

Snippet

Sponsor: Sanofi | Conditions: Rhinitis, Allergic, Perennial | Phase 3 | Status: COMPLETED